{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:47:13Z","timestamp":1793832433145,"version":"4.6.1"},"reference-count":61,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018002","name":"Taiwan Cancer Clinic Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100018002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031316","name":"Melissa Lee Cancer Foundation","doi-asserted-by":"publisher","award":["MLCF_10903"],"award-info":[{"award-number":["MLCF_10903"]}],"id":[{"id":"10.13039\/100031316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V111C-090"],"award-info":[{"award-number":["V111C-090"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Council, Taiwan","award":["NSTC 111-2628-E-A49-004-MY2"],"award-info":[{"award-number":["NSTC 111-2628-E-A49-004-MY2"]}]},{"name":"National Science and Technology Council, Taiwan","award":["NSTC 112-2314-B-075-009-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-075-009-MY3"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cholangiocarcinoma is a challenging malignancy with limited responses to conventional therapies, particularly immune checkpoint inhibitor therapy. Tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) are key components of the tumor microenvironment (TME) and have been implicated in the immune response to cancer. However, the role and difference of TLSs and TILs in patients with cholangiocarcinoma remains unclear. This study elucidates their contributions to the TME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined 16 tumor samples from a single-arm, phase II trial of nivolumab plus modified gemcitabine and S-1 and various datasets. Immunohistochemistry and RNA sequencing were employed to assess TLSs and TILs presence and activity. Differential gene expression and signature of immune cell composition were examined by GeoMx Digital Spatial Profiler and Cancer Transcriptome Altas analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TLS-positive (N=7) patients demonstrated significantly better immunotherapy outcomes compared with TLS-negative (N=9) patients, including higher objective response rates (71% vs 0%) and disease control rates (100% vs 67%). The presence of TLSs correlated with improved progression-free and overall survival (p=0.03). TLSs were associated with \u201cinflamed\u201d tumors characterized by substantial immune infiltration, particularly involving T and B cells. Gene expression analyses identified significant upregulation of B cell-related genes in TLSs. Additionally, TLSs exhibited higher properties of memory B cells and myeloid dendritic cells but lower levels of innate immune cells compared with TILs. T cells within TLSs showed elevated expression of precursor-exhausted-related genes and lower cytotoxicity signature. Furthermore, TILs in TLS-positive tumors had higher levels of exhaustion signatures compared with TILs in TLS-negative tumors. Clinical data corroborated these findings, with higher PD-L1 and LAG-3 expression in TLS-positive tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings revealed that TILs in TLS-positive tumors have more exhausted T cell signature and PD-1 and LAG-3 protein expression in CCA which support our clinical finding. TLSs can predict favorable immunotherapy responses in patients with cholangiocarcinoma, highlighting their potential as a biomarker and therapeutic target to enhance treatment efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010173","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:16:47Z","timestamp":1737980207000},"page":"e010173","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04172402","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6762-530X","authenticated-orcid":false,"given":"Shin-Yi","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Yeh","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Jung","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Shin-Shian","family":"Hsu","sequence":"additional","affiliation":[{"name":"Asclepiumm Taiwan Co., Ltd, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsien","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Lun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Sheng","family":"Hsu","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Yeh","sequence":"additional","affiliation":[{"name":"General Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Genomics Research Center, Academia Sinica, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-7393","authenticated-orcid":false,"given":"Ming-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"2025100309443662000_13.1.e010173.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"2025100309443662000_13.1.e010173.2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025100309443662000_13.1.e010173.3","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025100309443662000_13.1.e010173.4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14089"},{"key":"2025100309443662000_13.1.e010173.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"2025100309443662000_13.1.e010173.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69366-4","article-title":"High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer","volume":"10","author":"Ahn","year":"2020","journal-title":"Sci Rep"},{"key":"2025100309443662000_13.1.e010173.7","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-22-1152","article-title":"Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study","volume":"28","author":"Chiang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100309443662000_13.1.e010173.8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning Cold into Hot: Firing up the Tumor Microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"2025100309443662000_13.1.e010173.9","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390"},{"key":"2025100309443662000_13.1.e010173.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.04.010"},{"key":"2025100309443662000_13.1.e010173.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-021-01358-2"},{"key":"2025100309443662000_13.1.e010173.12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/d41586-019-03943-0","article-title":"New predictors for immunotherapy responses sharpen our view of the tumour microenvironment","volume":"577","author":"Bruno","year":"2020","journal-title":"Nature New Biol"},{"key":"2025100309443662000_13.1.e010173.13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000444357","article-title":"Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer","volume":"11","author":"Ingold Heppner","year":"2016","journal-title":"Breast Care (Basel)"},{"key":"2025100309443662000_13.1.e010173.14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"N Med"},{"key":"2025100309443662000_13.1.e010173.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"2025100309443662000_13.1.e010173.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30607-1"},{"key":"2025100309443662000_13.1.e010173.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front Immunol"},{"key":"2025100309443662000_13.1.e010173.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9"},{"key":"2025100309443662000_13.1.e010173.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.101"},{"key":"2025100309443662000_13.1.e010173.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674565","article-title":"Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies","volume":"12","author":"Tr\u00fcb","year":"2021","journal-title":"Front Immunol"},{"key":"2025100309443662000_13.1.e010173.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00619-z"},{"key":"2025100309443662000_13.1.e010173.22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153748","article-title":"Tertiary Lymphoid Structures as Mediators of Immunotherapy Response","volume":"14","author":"Vaghjiani","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025100309443662000_13.1.e010173.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.03.007"},{"key":"2025100309443662000_13.1.e010173.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.003"},{"key":"2025100309443662000_13.1.e010173.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78560-3","article-title":"Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure","volume":"10","author":"Lin","year":"2020","journal-title":"Sci Rep"},{"key":"2025100309443662000_13.1.e010173.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2025100309443662000_13.1.e010173.27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature New Biol"},{"key":"2025100309443662000_13.1.e010173.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"2025100309443662000_13.1.e010173.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"2025100309443662000_13.1.e010173.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6"},{"key":"2025100309443662000_13.1.e010173.31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450"},{"key":"2025100309443662000_13.1.e010173.32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/cco.2019.12.10","article-title":"Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)","volume":"9","author":"Jakubowski","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"2025100309443662000_13.1.e010173.33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1159\/000518104","article-title":"Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?","volume":"10","author":"Guti\u00e9rrez-Larra\u00f1aga","year":"2021","journal-title":"Liver Cancer"},{"key":"2025100309443662000_13.1.e010173.34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100309443662000_13.1.e010173.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001"},{"key":"2025100309443662000_13.1.e010173.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2025100309443662000_13.1.e010173.37","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jcmgh.2021.06.023","article-title":"Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice","volume":"12","author":"Delvecchio","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2025100309443662000_13.1.e010173.38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020367","article-title":"Turning Tertiary Lymphoid Structures (TLS) into Hot Spots: Values of TLS in Gastrointestinal Tumors","volume":"15","author":"Cai","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100309443662000_13.1.e010173.39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature New Biol"},{"key":"2025100309443662000_13.1.e010173.40","first-page":"100437","article-title":"PAX5 haploinsufficiency induced CD8+ T cells dysfunction or exhaustion by high expression of immune inhibitory-related molecules","volume":"28","author":"Liang","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"2025100309443662000_13.1.e010173.41","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.21037\/tcr-22-1759","article-title":"Immature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice","volume":"11","author":"Yin","year":"2022","journal-title":"Transl Cancer Res"},{"key":"2025100309443662000_13.1.e010173.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28020-5","article-title":"Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data","volume":"13","author":"Danaher","year":"2022","journal-title":"Nat Commun"},{"key":"2025100309443662000_13.1.e010173.43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0952"},{"key":"2025100309443662000_13.1.e010173.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.733800","article-title":"Control of Dendritic Cell Function Within the Tumour Microenvironment","volume":"13","author":"Gupta","year":"2022","journal-title":"Front Immunol"},{"key":"2025100309443662000_13.1.e010173.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02128.x"},{"key":"2025100309443662000_13.1.e010173.46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41423-020-00615-2","article-title":"A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves\u2019 orbitopathy","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025100309443662000_13.1.e010173.47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1583547","article-title":"APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures","volume":"8","author":"Morcrette","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100309443662000_13.1.e010173.48","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-189292","article-title":"Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft Versus Leukemia Response with Adoptive Cellular Therapy","volume":"142","author":"Maurer","year":"2023","journal-title":"Blood"},{"key":"2025100309443662000_13.1.e010173.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.06.025"},{"key":"2025100309443662000_13.1.e010173.50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105154","article-title":"T cell exhaustion initiates tertiary lymphoid structures and turbocharges cancer-immunity cycle","volume":"104","author":"Lin","year":"2024","journal-title":"EBioMedicine"},{"key":"2025100309443662000_13.1.e010173.51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32283-3","article-title":"A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"2025100309443662000_13.1.e010173.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.11.005"},{"key":"2025100309443662000_13.1.e010173.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01219-w"},{"key":"2025100309443662000_13.1.e010173.54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1058267","article-title":"Eomes is sufficient to regulate IL-10 expression and cytotoxic effector molecules in murine CD4+ T cells","volume":"14","author":"Thelen","year":"2023","journal-title":"Front Immunol"},{"key":"2025100309443662000_13.1.e010173.55","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2025100309443662000_13.1.e010173.56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700606"},{"key":"2025100309443662000_13.1.e010173.57","doi-asserted-by":"crossref","first-page":"865596","DOI":"10.3389\/fimmu.2022.865596","article-title":"CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"2025100309443662000_13.1.e010173.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.02.001"},{"key":"2025100309443662000_13.1.e010173.59","doi-asserted-by":"crossref","unstructured":"Peyraud F , Guegan JP , Rey C , et al . Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy. J C O 2022;40. doi:10.1200\/JCO.2022.40.16_suppl.2596","DOI":"10.1200\/JCO.2022.40.16_suppl.2596"},{"key":"2025100309443662000_13.1.e010173.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.030"},{"key":"2025100309443662000_13.1.e010173.61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166497","article-title":"Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma","volume":"14","author":"Shang","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:44:51Z","timestamp":1759509891000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-010173"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010173","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}